<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767688</url>
  </required_header>
  <id_info>
    <org_study_id>3102-031</org_study_id>
    <nct_id>NCT01767688</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-3102 in Patients With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate and compare the pharmacokinetics of a single 25-mg dose of
      MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
      The primary hypothesis is that in participants with moderately impaired hepatic function, the
      area under the concentration-time curve from time zero to infinity (AUC0-∞) is similar to
      that observed in healthy matched control participants following a single 25 mg oral dose of
      MK-3102. Specifically, the true ratio (moderately impaired hepatic function patients/healthy
      matched control subjects) of geometric means for AUC0-∞ is no greater than 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2013</start_date>
  <completion_date type="Actual">March 7, 2013</completion_date>
  <primary_completion_date type="Actual">March 1, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Hour 0 to 168 Hours After Dosing (AUC0-168h)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at 168 Hours After Dosing (C168h)</measure>
    <time_frame>168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Drug Concentration (Tmax)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Phase Half-life (t½)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 14 days post-dose</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinued From Study Due to AEs</measure>
    <time_frame>Up to 14 days post-dose</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Matched Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3102</intervention_name>
    <description>Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.</description>
    <arm_group_label>Moderate Hepatic Impairment Group</arm_group_label>
    <arm_group_label>Healthy Matched Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Impaired Hepatic Function Participants:

          -  A diagnosis of:

               1. Chronic (&gt; 6 months) hepatic insufficiency

               2. Stable (no acute episodes of illness within the previous 2 months due to
                  deterioration in hepatic function) hepatic insufficiency with features of
                  cirrhosis due to any etiology

          -  Score on the Child-Pugh Scale of 7 to 9 (moderate hepatic insufficiency)

          -  Estimated creatinine clearance (CLCr) &gt; 60 mL/min or glomerular filtration rate (eGFR)
             ≥ 60 mL/min/1.73 m^2

        Both Impaired Hepatic Function and Healthy Participants:

          -  In general good health

          -  Continuous non-smokers or moderate smokers for at least 3 months prior to study start

          -  Body Mass Index ≤39 kg/m^2

          -  Females of reproductive potential must have a negative pregnancy test and agree to use
             acceptable birth control method(s) or remain sexually inactive throughout study

          -  Non-vasectomized male patients must agree to use acceptable birth control method(s) or
             abstain from sexual intercourse during the trial and for 3 months after the study

        Exclusion Criteria:

        Healthy Participants:

          -  History or presence of alcoholism within the past 2 years

          -  Presence of hepatitis B virus (HBV) or hepatitis virus C (HVC)

        Both Impaired Hepatic Function and Healthy Participants:

          -  History or presence of drug abuse within the past 2 years

          -  History or presence of human immunodeficiency virus (HIV)

          -  History or presence of significant cardiovascular, pulmonary, renal, hematologic,
             gastrointestinal (other than hepatic impairment), endocrine, immunologic,
             dermatologic, or neurological disease

          -  Use of any medication or substance (including prescription or over the counter, health
             supplements, natural or herbal supplements) which cannot be

        discontinued at least 14 days prior to the study start and throughout the study

          -  Has been on a special diet within 28 days prior to the study start

          -  Blood donation within 56 days or plasma donation within 7 days prior to study start

          -  Participation in another clinical trial within 28 days of study start

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <results_first_submitted>September 29, 2015</results_first_submitted>
  <results_first_submitted_qc>September 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2015</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=3102-031&amp;kw=3102-031&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult (18 to 80 years of age) males and females participated in the study. Eight participants with moderate hepatic impairment, and eight healthy control participants (matched according to age, weight, gender, and creatinine clearance [CLCr] or estimated glomerular filtration rate [eGFR]), were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Matched Control Group</title>
          <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Matched Control Group</title>
          <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="6.45" lower_limit="45" upper_limit="62"/>
                    <measurement group_id="B2" value="53" spread="8.45" lower_limit="41" upper_limit="68"/>
                    <measurement group_id="B3" value="55" spread="7.55" lower_limit="41" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞)</title>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="20.2" upper_limit="26.9"/>
                    <measurement group_id="O2" value="24.9" lower_limit="21.8" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio (GMR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Versus Time Curve From Hour 0 to 168 Hours After Dosing (AUC0-168h)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Hour 0 to 168 Hours After Dosing (AUC0-168h)</title>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="19.8" upper_limit="25.4"/>
                    <measurement group_id="O2" value="23.8" lower_limit="21.2" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio (GMR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration at 168 Hours After Dosing (C168h)</title>
        <time_frame>168 hours post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at 168 Hours After Dosing (C168h)</title>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="10.7" upper_limit="23.0"/>
                    <measurement group_id="O2" value="19.4" lower_limit="13.7" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio (GMR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572" lower_limit="523" upper_limit="626"/>
                    <measurement group_id="O2" value="554" lower_limit="511" upper_limit="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least-squares mean ratio (GMR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Drug Concentration (Tmax)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Drug Concentration (Tmax)</title>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Phase Half-life (t½)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96, and 168 hours post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Phase Half-life (t½)</title>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="17.4"/>
                    <measurement group_id="O2" value="34.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Adverse Events (AEs)</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 14 days post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AEs)</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinued From Study Due to AEs</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 14 days post-dose</time_frame>
        <population>All participants that received omarigliptin 25 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Matched Control Group</title>
            <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinued From Study Due to AEs</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient/subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>All participants that received omarigliptin 25 mg.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were monitored for 14 days after receiving omarigliptin 25 mg.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>Participants with Child-Pugh scores of 7-9 were enrolled in the Moderate Hepatic Impairment group.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Matched Control Group</title>
          <description>Healthy participants matched according to mean age (±15 years), mean weight (±10 kg), and mean CLCr (±20 mL/min) or mean eGFR (±20 mL/min/1.73 m²) to same-gender participants with moderate hepatic impairment were enrolled in the Control group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v.15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

